Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB...
Transcenta Therapeutics says it will grant WuXi Biologics and its affiliates a non-exclusive license to certain technologies relating to Transcenta’s intensified continuous bioprocessing (HiCB) platform and ExcelPro cell culture media.
Transcenta will receive an upfront payment of $1.5 million and will be eligible for milestone payments upon the achievement of specified conditions. Through this collaboration, WuXi Biologics will become Transcenta’s strategic partner for CMC development and supporting molecules across Transcenta’s development pipeline.
A Transcenta spokesperson explained that the HiCB platform integrates intensified continuous perfusion upstream processing with hybrid continuous downstream purification, enabling a step-change in productivity, achieving an increase in productivity compared with conventional fed-batch processes.
HiCB can significantly reduce cost of goods, lower capital investment, and enable agile production, claims the company official, while providing a solution for improving recovering yield and product quality for complex biologics.
Transcenta, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company with expertise in biologics discovery, translational research, clinical, and process development. The company develops a pipeline of over ten therapeutic antibody candidates spanning oncology, bone, and kidney disorders.
NewsBioprocessingCell cultureKidney diseasesTranslational researchTranscenta TherapeuticsWuXi BiologicsHiCBPrevious article
Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma FirmNext article
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MiceAlso of Interest
Smarter Cell Culture Starts with Better MediaHarnessing Real-Time DataMicroscale Chromatography Moves Toward Manufacturing ReadinessMicro-Bladder Model Demonstrates How Phage Therapy Could Help to Reduce Recurrent UTIsThe DNA Balancing Act in Boosting Bacterial ProductivityCutting Costs in Serum-Free FGF2 Processing with Recycled MediaRelated Media
Boston's Bioprocessing Buzz:GENReports Live from BPI 2025Bioprocessing in Boston: GEN Reports Live from BPI 2024Bioprocessing in Beantown: GEN Reports Live from Day 2 at BPIBreathing Oxygen Back into the Biological ConversationGlobal Single-Use Network Support Assurance of SupplyResins Address Downstream Purification ConcernsTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
